Steve Mandel's Lone Pine Capital disclosed a portfolio restructuring across 47 positions in its Q4 2024 13F filing, reducing equity exposure by $2.8 billion while increasing cash reserves to 11% of assets under management. The firm exited nine positions entirely, including a $340 million stake in a cloud infrastructure company held since 2021, and trimmed 14 existing holdings by an average of 28%.

The filing shows Lone Pine added three new biotech positions totaling $620 million, with the largest a $280 million stake in a clinical-stage oncology developer trading at 4.2x price-to-sales. The firm also increased its consumer discretionary allocation by $410 million, concentrated in two retail names with average revenue growth of 18% year-over-year. Technology remains the largest sector weight at 42% of the portfolio, down from 51% in Q3.

The cash build matters because Lone Pine historically runs 3-5% cash in normal conditions. The move to 11% suggests either tactical caution on valuations or positioning for faster deployment into correction opportunities. The firm's average holding period is 22 months, and the last time cash exceeded 9% was Q1 2020, three weeks before the March bottom. Portfolio concentration also shifted, with the top ten holdings now representing 68% of disclosed equity value, up from 61% last quarter.

Allocators tracking Lone Pine's style should note the biotech additions carry higher beta—all three names trade with 90-day volatility above 45%—and two are pre-revenue. The consumer picks both report earnings within 28 days, providing near-term catalysts that could validate or punish the thesis quickly. The technology trims were not uniform: the firm added $180 million to one semiconductor position while cutting two software names by a combined $520 million, suggesting sector rotation rather than broad de-risking.

The firm now holds $7.2 billion in disclosed long equity across 38 names, with 16% of the portfolio in positions initiated or materially expanded in the past six months. The next 13F filing will reflect Q1 2025 holdings and is due by mid-May.